TrialMenopause (New York, N.Y.)2020

A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.

Graeme L Fraser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.